Trametinib derives its clinical anti-cancer efficacy from promoting the interaction of its primary targets MEK1/2 with KSR1/2, but has low affinity for KSR1 or KSR2 alone, meaning this interaction was missed during clinical development1. Here, KSR1 is linked to cancer.